Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	664.65B
Revenue (ttm)	211.13B
Net Income (ttm)	17.80B
Shares Out	12.42M
EPS (ttm)	1,290.73
PE Ratio	41.45
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,204
Average Volume	209,849
Open	55,500
Previous Close	55,500
Day's Range	52,500 - 55,500
52-Week Range	18,510 - 61,700
Beta	-0.17
RSI	64.87
Earnings Date	Nov 14, 2025

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2000
• Employees: 425
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940

Financial Performance

In 2024, Kolon Life Science's revenue was 161.39 billion, an increase of 29.48% compared to the previous year's 124.64 billion. Losses were -93.09 billion, 203.0% more than in 2023.